Novo Nordisk recently broke ground on its new diabetes medicine production facility that is located in Clayton, North Carolina, where locals anticipate the estimated 700 jobs they hope the facility will generate.
Over 100 community members, policy makers and employees were present at the ceremonial groundbreaking event.
"As the prevalence of diabetes has grown in the U.S., so too has the demand for effective treatments," Lars Sørensen, president and CEO of Novo Nordisk, said. "It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organization. This site will play a vital role in enabling us to meet the needs of people living with diabetes in the U.S. for years to come."
The new facility will be used to manufacture active pharmaceutical ingredients (API) for a variety of the current as well as future insulin and GLP-1 medicines at Novo Nordisk.
"Novo Nordisk's billion dollar decision to bring this landmark manufacturing facility to North Carolina underscores its commitment to our state and confidence in our state's talent," Pat McCrory, governor of North Carolina, said. "This expansion of the current site and workforce highlights our ability to be a leader in bio-manufacturing at the global level."
The new facility will be completely operational in 2020. It will guarantee that there are enough diabetes medicines produced for the future of the U.S.